Reportstack has announced a new report on Parkinson’s Disease – Global Drug Forecast and Market Analysis to 2022. According to this report, the US will have the largest PD therapeutics market share of 44% by 2022, expanding from 32% in 2012. This will be followed by Japan, Brazil and Germany, with respective shares of 13%, 11% and 10%. Heather Leach, GlobalData’s Healthcare Analyst, says: “PD therapy is currently limited to symptomatic treatment, but since this is a chronic and progressive disorder, patients and physicians are waiting anxiously for a treatment that slows or stops this progression. “Several strategies are already under investigation, including compounds or biological agents that administer growth factors, prevent neuroinflammation and target α-synuclein.”
While GlobalData does not expect a disease-modifying treatment to be introduced during the forecast period, several pipeline programs are underway to reach this goal. Leach says: “Most of the late-stage pipeline agents are set to meet the needs of advanced patients, with five therapies expected to launch by 2022. These include Rytary, Civitas’ CVT-301, opicapone, safinamide, and tozadenant. Of these, CVT-301, opicapone, and tozadenant will be used almost exclusively in advanced patients.” Current unmet needs in the PD treatment market, such as complications in advanced-stage patients known as wearing-off and dyskinesia, will also be addressed during the forecast period. “During the coming decade, wearing-off will most likely be addressed by CVT-301 directly. Other pipeline therapies, including Rytary and opicapone, may also prevent the emergence of wearing-off symptoms,” Leach concludes.
The companies mentioned in this report are Merck, Roche, AbbVie, UCB, GlaxoSmithKline, Novartis, Orion, Newron, Lundbeck and Civitas. The markets covered in this report are US, France, Germany, Italy, Spain, UK, Japan, and Brazil. The key findings in this report are - Population increases, especially in the elderly, will be a key driving force in the global PD market, With several small biotech and pharmaceutical companies involved in mid-stage development of PD products, there will be ample opportunity for partnerships with Big Pharma, Levodopa based therapy will remain the gold standard of care with advancements in administration, including the introduction of slow-release formulations and an emergency use inhaler and Several unmet needs are expected to remain after the forecast period, as advancements in the control of non-motor symptoms and in the development of disease-modifying therapies are lagging. More details about this report can found by visiting Parkinson’s Disease (PD)treatment market report link.